Adicet Bio, Inc. announced on July 22, 2025, a 30% workforce reduction and expects restructuring charges of approximately $2.3 million; they also decided to focus on their ADI-001 and ADI-212 products while discontinuing ADI-270, which had shown a 100% disease control rate in a Phase 1 trial. This strategic shift aims to optimize their pipeline and extend their cash runway into late 2026.